Advertisement

Topics

AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug

08:28 EDT 18 Aug 2017 | Labiotech.eu

AstraZeneca and its partner MSD have announced that the FDA has granted approval to Lynparza as a treatment for several forms of recurrent cancer. Lynparza (olaparib) is now an oral treatment intended to reduce relapse in patients with recurrent ovarian, ...

This awesome article AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca and MSD Expand Use of Oral Ovarian Cancer Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...